RxDoctor Payments Data

Carla Dyer, APRN

Psychiatric/Mental Health · Sandy Hook, KYNPI 1033468939

Payments from drug & device makers

$6,165in general payments, 2019–2025

Across 311 payments — averaging $19.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alkermes, Inc.$1K
  • Johnson & Johnson$838
  • Teva Pharmaceuticals USA, Inc.$560
  • Otsuka America Pharmaceutical, Inc.$412
  • Vanda Pharmaceuticals Inc.$371
  • plus $2K from 11 others

What the payments were for

  • Food & beverage$5,73893%
  • Education$4277%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,165 in reported general payments places this provider in the 90th percentile of 946 psychiatric/mental health providers in Kentucky.

See all psychiatric/mental health providers in Kentucky

Medicare billing

Part B allowed, 2024
$7,934
Medicare patients
40
Services billed
159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate56$192,677
LybalviOlanzapine/Samidorphan Malate18$39,910
VraylarCariprazine Hcl23$33,915
Atomoxetine Hcl12$3,010
Hydroxyzine Pamoate126$2,782
Aripiprazole41$2,597
Lamotrigine ErLamotrigine12$2,430
Ziprasidone Hcl33$2,317
Buspirone Hcl172$1,985
Paliperidone ErPaliperidone13$1,694
Olanzapine56$1,298
Mirtazapine69$881
Lurasidone Hcl13$789
Risperidone96$770
Sertraline Hcl130$748

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$838$192,67756 claims
Alkermes, Inc.Lybalvi$1,040$39,91018 claims
AbbVieVraylar$1,218$33,91523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 946 psychiatric/mental health providers in Kentucky.

Other psychiatric/mental health in Sandy Hook

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →